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Abstract
Background: We aimed to explore the agreement among World Health Organization (WHO),
European Group for the Study of Insulin Resistance (EGIR), National Cholesterol Education
Program (NCEP), American College of Endocrinology (ACE), and International Diabetes
Federation (IDF) definitions of the metabolic syndrome.
Methods: 1568 subjects (532 men, 1036 women, mean age 45 and standard deviation (SD) 13
years) were evaluated in this cross-sectional, methodological study. Cardiometabolic risk factors
were determined. Insulin sensitivity was calculated by HOMA-IR. Agreement among definitions was
determined by the kappa statistic. ANOVA and post hoc Tukey's test were used to compare
multiple groups.
Results: The agreement between WHO and EGIR definitions was very good (kappa: 0.83). The
agreement between NCEP, ACE, and IDF definitions was substantial to very good (kappa:
0.77–0.84). The agreement between NCEP or ACE or IDF and WHO or EGIR definitions was fair
(kappa: 0.32–0.37). The age and sex adjusted prevalence of metabolic syndrome was 38% by NCEP,
42% by ACE and IDF, 20% by EGIR and 19% by WHO definition. The evaluated definitions were
dichotomized after analysis of design, agreement and prevalence: insulin measurement requiring
definitions (WHO and EGIR) and definitions not requiring insulin measurement (NCEP, ACE, IDF).
One definition was selected from each set for comparison. WHO-defined subjects were more
insulin resistant than subjects without the metabolic syndrome (mean and SD for log HOMA-IR,
0.53 ± 0.14 vs. 0.07 ± 0.23, respectively, p < 0.05) and had higher Framingham risk scores (mean
and SD, 2.99 ± 4.64% vs. 1.10 ± 1.87%, respectively, p < 0.05). The additional subjects identified by
IDF definition, but not by WHO definition also had more insulin resistance and higher Framingham
risk scores than subjects without the metabolic syndrome (mean and SD, log HOMA-IR 0.18 ± 0.18
vs. 0.07 ± 0.23, p < 0.05 and Framingham risk score 2.93 ± 4.54% vs. 1.10 ± 1.87%, p < 0.05). The
IDF-identified additional subjects had similar Framingham risk scores as WHO-identified subjects
(p > 0.05), but lower log HOMA-IR values (p < 0.05).
Conclusion: The metabolic syndrome definitions that do not require measurement of insulin
levels (NCEP, ACE and IDF) identify twice more patients with insulin resistance and increased
Framingham risk scores and are more useful than the definitions that require measurement of
insulin levels (WHO and EGIR).
Published: 19 December 2007
BMC Public Health 2007, 7:353 doi:10.1186/1471-2458-7-353
Received: 14 November 2007
Accepted: 19 December 2007
This article is available from: http://www.biomedcentral.com/1471-2458/7/353
© 2007 Can and Bersot; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Public Health 2007, 7:353 http://www.biomedcentral.com/1471-2458/7/353
Page 2 of 9
(page number not for citation purposes)
Background
The term "metabolic syndrome" describes clustering of
cardiovascular disease (CVD) risk factors of metabolic ori-
gin [1,2]. A two-fold increase in the risk of CVD and a five-
fold increase in the risk of type 2 diabetes mellitus accom-
pany the metabolic syndrome [3-8]. World Health Organ-
ization (WHO) was the first to propose criteria for
diagnosis of the metabolic syndrome [9], followed by the
European Group for the Study of Insulin Resistance
(EGIR) [10], National Cholesterol Education Program
(NCEP) Adult Treatment Panel III [1], American College
of Endocrinology (ACE) [11], and International Diabetes
Federation (IDF) [12]. Although these organizations pro-
posed to measure the same components, they suggested
different combinations and different cut-off points. In
WHO and EGIR definitions, the presence of insulin resist-
ance was the starting point. In IDF definition, central
obesity was the prerequisite of the metabolic syndrome.
Components of the metabolic syndrome were selected by
these organizations, because they tend to cluster com-
monly in insulin resistant individuals who are at
increased risk of CVD, beyond the risk implicated by clas-
sical CVD risk factors, like elevated low density lipopro-
tein cholesterol (LDL-C) levels [5,8,13-15]. Therefore, the
metabolic syndrome has been assigned as a secondary tar-
get for intervention by NCEP Adult Treatment Panel III.
So far information on the agreement among all of the five
definitions of the metabolic syndrome is limited, espe-
cially data on IDF definition is recently accumulating
[5,16-24]. The aim of our study was to assess the agree-
ment among various definitions of the metabolic syn-
drome and to explore the differences in anthropometric
and metabolic variables among WHO, EGIR, NCEP, ACE
and IDF definition-identified subjects.
Methods
This was a methodological analysis based on data derived
from the Turkish Heart Study, a cross-sectional epidemio-
logical survey of CVD risk factors in Turkish adults [25].
Information about past medical history, family history,
demographic characteristics, socioeconomic status, physi-
cal activity level, smoking, and drinking habits was
obtained with a physician interview. Subjects were classi-
fied as low income, if the monthly household income was
less than $500; as low education level if they were illiter-
ate, literate only or had five years or less of elementary
school education. Subjects who report less than one hour
of physical exercise per week were classified as sedentary.
Subjects who consumed at least one alcoholic beverage
per month were assigned to the drinker category. Family
history was obtained for first degree relatives. Body mass
index (BMI) was calculated as weight in kilograms over
squared height in meters. Height was measured to within
0.5 cm with a measuring stick, weight to within 0.1 kg
with a digital scale, waist and hip circumference to the
nearest 0.5 cm. Waist circumference was measured at the
midway between lower margin of the rib cage and the
superior iliac crest during mild expiration. Hip circumfer-
ence was measured at the greater trochanteric level with a
measuring tape. All measurements were taken with shoes
removed and with participants wearing light clothing.
Blood pressure was measured on the right arm with an
automated sphygmomanometer (Omron automatic
blood pressure monitor with IntelliSense®, Bannockburn,
Illinois, USA) after fifteen minute of rest with the subject
in the sitting position. The mean of two recordings, five
minutes apart was recorded.
Subjects were invited to the study from the offices of local
governors by our staff and with posted fliers. No financial
incentive was paid to the participants. More explanation
about subject recruitment was provided in Additional file
1. 1700 subjects participated to the study in 2003. One
hundred and nineteen subjects (7%) with past history of
or newly diagnosed diabetes mellitus were excluded from
this analysis because ACE and EGIR exempted diabetics
from their definitions. Eleven subjects below the age of 20
and two pregnant subjects were also excluded. There are
1568 subjects, 532 men (34%) and 1036 women (66%)
in this analysis. 1050 participants (67%) were from Istan-
bul, an urban area and 518 participants (33%) were from
Kayseri, a rural area. Six percent (n = 95) of the subjects
had a history of self-reported cardiovascular disease. Fifty-
four subjects (3%) were taking lipid lowering medica-
tions. Forty-five subjects were taking statins, three subjects
fibrates, six subjects omega-3 fatty acids and none of the
subjects were taking niacin or resins. Two hundred and
thirty-six subjects (15%) were taking antihypertensive
agents. General characteristics of the study subjects are
given in Table 1. The study procedures were approved by
the Committee on Human Research of the University of
California, San Francisco and permission to conduct the
study was granted by the Ministry of Health, Republic of
Turkey. All subjects signed written informed consent.
Blood was collected after a 10-hour fast. Kits from Boe-
hringer-Mannheim (Mannheim, Germany) were used for
lipid and glucose analyses. A multichannel analyzer (H
917, Hitachi, Tokyo, Japan) was used for colorimetric
enzymatic determinations of cholesterol (kit: Monotest
Cholesterol with cholesterol esterase, cholesterol oxidase
and peroxidase (CHOD-PAP)), triglycerides (kit: Perido-
chrom Triglyceride with glycerol phosphate oxidase and
peroxidase (GPO-PAP)) and glucose (kit: Glucose, glu-
cose oxidase and peroxidase (GOD-PAP)). LDL choles-
terol (LDL-C) was calculated by the Friedewald equation
[26] for participants with triglyceride levels < 500 mg/dl.
A homogenous assay for measuring HDL levels was used.
Fasting insulin levels were measured with an electrochem-
iluminescence immunoassay (Roche Elecsys 2010, RocheBMC Public Health 2007, 7:353 http://www.biomedcentral.com/1471-2458/7/353
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Diagnostics, kit: Insulin). Insulin sensitivity was esti-
mated with Homeostasis Model Assessment (HOMA-IR)
equation. HOMA-IR equals fasting serum insulin (μU/ml)
times fasting plasma glucose (mmol/l) divided by 22.5
[27]. Biochemical analyses were performed at the Ameri-
can Hospital Clinical Laboratory in Istanbul, as it is certi-
fied as a reference laboratory by the Centers for Disease
Control (Atlanta, Georgia, USA).
The WHO, EGIR, NCEP, ACE, and IDF criteria for meta-
bolic syndrome is outlined in Table 2. American Heart
Association and National Heart Lung and Blood Institute
modified NCEP criteria by decreasing the glucose cut-off
from 6.1 to 5.6 mmol/l and assigned patients on drug
therapy for hypertension, hypertriglyceridemia, and low
HDL-C levels to positive components [28]. We used the
modified NCEP criteria. EGIR defines insulin resistance,
as plasma insulin levels above 75th percentile [10]. The
75th percentile value of insulin distribution in our study
sample of nondiabetic individuals was 73.2 pmol/l (10.2
μU/ml). Similar to EGIR, WHO designates insulin resist-
ance as a prerequisite for the diagnosis of the metabolic
syndrome. WHO defines insulin resistance as "under eug-
lycemic hyperinsulinemic conditions, glucose uptake
below the lowest quartile for background population
under investigation" [9]. As euglycemic hyperinsulinemic
clamp studies are not routinely performed in clinical prac-
tice and they are time consuming and costly, we used
HOMA-IR to define insulin resistance. A similar modifica-
tion was used in previous studies [4,7]. We designated the
subjects in the upper quartile of the HOMA-IR distribu-
tion as insulin resistant. The 75th percentile HOMA-IR
value in nondiabetic subjects was 2.32 in this study. As
urinary microalbumin excretion was not ascertained in
this study, it was not counted as a component in the
WHO-defined metabolic syndrome. Oral glucose toler-
ance test was not performed and postprandial glucose
results were not included in the glucose component of
ACE and WHO definitions.
The Statistical Package for Social Sciences software, ver-
sion 15.0 (SPSS Inc., Chicago, Illinois, USA) was used for
statistical analyses. Data were summarized by calculating
mean ± standard deviation for quantitative variables and
percentages for categorical variables. The agreement
between five definitions of the metabolic syndrome was
determined by the kappa statistic (κ). The level of agree-
ment is considered poor with κ ≤ 0.20, fair with κ = 0.21
to 0.40, moderate with κ = 0.41 to 0.60, substantial with
Table 1: General characteristics of the subjects.
All Men Women
n 1568 532 1036
Age (years)* 45 ± 13 45 ± 13 45 ± 13
Low income† 72% 59% 78%
Low education† 60% 43% 69%
Sedentary† 73% 65% 77%
Current smoker† 26% 40% 19%
Drinker† 22% 42% 11%
BMI (kg/m2)* 29 ± 5 28 ± 4 30 ± 5
Waist (cm)* 94.6 ± 12.3 99.6 ± 10.2 92.1 ± 12.5
Glucose (mmol/l)* 5.0 ± 0.6 5.1 ± 0.5 5.0 ± 0.6
Insulin (pmol/l)‡ 51.7 
(35.9, 73.2)
52.4 
(35.9, 78.2)
50.9 
(35.9, 71.8)
HOMA-IR‡ 1.57 
(1.08, 2.32)
1.65 
(1.12, 2.47)
1.53 
(1.05, 2.30)
TC (mmol/l)* 4.75 ± 1.02 4.70 ± 0.93 4.77 ± 1.06
HDL-C (mmol/l)* 1.15 ± 0.31 1.00 ± 0.25 1.23 ± 0.31
LDL-C (mmol/l)* 2.92 ± 0.88 2.91 ± 0.82 2.93 ± 0.91
Triglyceride (mmol/l)‡ 1.26 
(0.91, 1.77)
1.45 
(1.01, 2.09)
1.19 
(0.86, 1.65)
Please see list of abbreviations used. *mean ± SD are given for 
normally distributed variables, †percentage values are given for 
categorical variables ‡median (25th and 75th percentile values) are 
given for variables with a skewed distribution
Table 2: Criteria for clinical diagnosis of the metabolic syndrome.
WHO EGIR NCEP ACE IDF
Prerequisite DM, IFG, IGT, IR insulin in top 25% None high risk* WC ≥ 94 cm (men), 
WC ≥ 80 cm (women)†
No of criteria and ≥ 2 of and ≥ 2 of ≥ 3 of and ≥ 2 of and ≥ 2 of
Obesity BMI > 30 and/or WHR > 0.9 
(men), WHR > 0.85 (women)
WC ≥ 94 cm (men), 
WC ≥ 80 cm (women)
WC ≥ 102 cm (men), 
WC ≥ 88 cm (women)
BP (mmHg) ≥ 140/90 ≥ 140/90‡ ≥ 130/85‡ >130/85 ≥ 130/85‡
HDL-C (mmol/l) <0.9 (men), <1.0 (women)§ 
or
<1.0‡§ or <1.0 (men), <1.3 
(women)‡
<1.0 (men), <1.3 
(women)
<1.0 (men), <1.3 
(women)‡
TG (mmol/l) ≥ 1.7 >2.0‡ ≥ 1.7‡ >1.7 >1.7‡
Glucose (mmol/l) ≥ 6.1, IGT ≥ 6.1 || ≥ 5.6‡ ≥ 6.1, IGT || ≥ 5.6‡
Please see list of abbreviations used. *high risk: diagnosis of CVD, hypertension, polycystic ovary syndrome, nonalcoholic fatty liver disease, or 
acanthosis nigricans; family history of type 2 diabetes, hypertension, or CVD; history of gestational diabetes or glucose intolerance; Non-Caucasian 
ethnicity, sedentary lifestyle, BMI > 25 kg/m2 or WC > 94 cm (men), >80 cm (women); and age >40 years [11]. †cut-off values differ according to 
ethnic origin [12]. ‡or treated for this abnormality. §lipid criterion consists of elevated triglycerides and/or low HDL in WHO and EGIR definitions 
and is counted as one component. || excludes patients with diabetes.BMC Public Health 2007, 7:353 http://www.biomedcentral.com/1471-2458/7/353
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κ = 0.61 to 0.80, and very good with κ > 0.80 [29]. Age and
sex adjusted prevalence of the metabolic syndrome was
calculated separately for each definition. Information
from the Republic of Turkey, Ministry of Interior Affairs,
Office of Population and Citizenship 2003 household
survey was used to adjust the prevalence rates by the direct
method [30]. Ten year risk of coronary heart disease was
calculated from Framingham risk tables [1]. One-way
ANOVA was performed in order to analyze mean differ-
ences among multiple groups. When significant differ-
ences were found, post hoc Tukey's test was performed for
identifying the source of these differences.
Results
The age and sex adjusted prevalence of the metabolic syn-
drome was 38% by NCEP, 42% by ACE and IDF, 20% by
EGIR, and 19% by WHO definition. The age and sex
adjusted prevalence of each metabolic syndrome compo-
nent was as follows: waist circumference according to
NCEP criteria: 49%, waist circumference according to IDF
criteria: 73%, elevated triglycerides (NCEP): 28%, low
HDL-C (NCEP): 61%, elevated blood pressure (NCEP):
56%, elevated glucose (NCEP, excluding diabetes): 15%.
The agreement among all of the five published definitions
of the metabolic syndrome is shown in Table 3. The agree-
ment among NCEP, ACE, and IDF definitions was sub-
stantial to very good. The agreement between WHO and
EGIR definitions was also very good. The agreement
between NCEP or ACE or IDF and WHO or EGIR defini-
tions was fair and κ value ranged from 0.32 to 0.37. The
agreement among metabolic syndrome definitions was
further assessed according to geographic area and gender
(Table 3a and Table 3b in Additional file 2). Forty-six per-
cent (n = 722) of our study sample was categorized as not
having the metabolic syndrome and 14% (n = 224) as
having the metabolic syndrome, concordantly according
to all five definitions. Seventy-seven percent (n = 1203) of
the subjects was categorized as not having and 18% (n =
279) as having the metabolic syndrome for both WHO
and EGIR definitions. Forty-nine percent (n = 766) of the
participants was categorized as not having the metabolic
syndrome and 37% (n = 575) as having the metabolic
syndrome concordantly by NCEP, ACE and IDF defini-
tions.
Anthropometrics, biochemical data and Framingham risk
scores of subjects categorized as metabolic syndrome
according to each definition are provided in Table 4. All of
the WHO definition, 92% of EGIR, 44% of NCEP, 40% of
ACE, and 42% of IDF definition-identified subjects had
insulin resistance, as defined being in the top quartile of
HOMA-IR distribution in our sample. The frequency of
insulin resistance in subjects free of the metabolic syn-
drome according to any of the definitions was less than
14%. Table 4 shows that each definition of the metabolic
syndrome identifies a subset of individuals from the study
population with almost the same characteristics. The most
striking differences are in the prevalence rates, fasting
insulin levels and HOMA-IR values. Our data (Table 3 and
4) indicate that definitions of the metabolic syndrome
can be dichotomized into two sets: the first set, NCEP,
ACE and IDF, and the second set, WHO and EGIR defini-
tions. The most prominent feature of the first set is that
NCEP, ACE and IDF definitions do not require the meas-
urement of insulin levels in their criteria, whereas the sec-
ond set, WHO and EGIR definitions do require the
assessment of insulin sensitivity or insulin levels. Preva-
lence estimates show that the first set of definitions cate-
gorizes twice more subjects as metabolic syndrome cases
than the second set. In view of these results, we wished to
assess in which metabolic variables the surplus subjects,
differed from subjects free of the metabolic syndrome or
from subjects identified by an insulin measurement
requiring definition. One definition from each set was
selected for this purpose, for example WHO and IDF def-
initions. Subjects who do not have the metabolic syn-
drome according to WHO definition constituted the first
group. The second group was subjects with the metabolic
syndrome according to WHO definition including sub-
jects who concordantly satisfy the IDF definition at the
same time. The third group was subjects with surplus met-
abolic syndrome, indicating those categorized as meta-
bolic syndrome cases only by IDF definition, but not by
WHO definition (see Table 5). Subjects with the meta-
bolic syndrome according to WHO definition had signifi-
cantly higher insulin levels and Framingham risk scores
than subjects without the metabolic syndrome. Surplus
subjects classified as metabolic syndrome by IDF but not
by WHO definition also had significantly higher fasting
insulin levels than subjects without the metabolic syn-
drome. The Framingham risk scores of surplus-metabolic
syndrome subjects were also significantly higher than sub-
jects without the metabolic syndrome. Subjects with IDF-
defined surplus metabolic syndrome had slightly but sig-
nificantly lower BMI, waist circumference, diastolic blood
pressure, insulin, HOMA and triglyceride values than sub-
jects with WHO-defined metabolic syndrome. There were
no differences in the Framingham risk scores between
WHO- and surplus IDF-defined subjects with the meta-
bolic syndrome. We replaced EGIR for WHO definition
Table 3: Agreement between each definition of the metabolic 
syndrome.
NCEP IDF ACE WHO EGIR
NCEP * 0.84 0.77 0.37 0.37
IDF * 0.81 0.33 0.35
ACE * 0.32 0.34
WHO * 0.83
EGIR *
Please see list of abbreviations used. n = 1568BMC Public Health 2007, 7:353 http://www.biomedcentral.com/1471-2458/7/353
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and NCEP and ACE for IDF definition and repeated the
comparison in the same manner. These comparisons are
provided in tables 6-10 in Additional files 3, 4, 5, 6, 7.
Subjects with the metabolic syndrome as defined either by
WHO and EGIR criteria had an adverse CVD risk factor
profile compared with subjects without the metabolic
syndrome. Surplus metabolic syndrome subjects defined
by IDF, NCEP or ACE definition had higher BMI, waist cir-
cumference, SBP, DBP; glucose, insulin, HOMA-IR, TC,
and TG values and lower HDL-C values than subjects
without the metabolic syndrome. Surplus metabolic syn-
drome (IDF-, NCEP-, ACE-defined) cases had slightly, but
significantly lower BMI, waist circumference, insulin,
HOMA-IR and TG values than subjects identified by an
insulin measurement requiring definition (WHO or
EGIR). Except for minimal differences in systolic blood
pressure (up to 3 mmHg), total cholesterol level (up to
0.15 mmol/l) and log triglycerides (up to 0.05), surplus
metabolic syndrome cases had the same degree of impair-
ment in measured variables whether they were catego-
rized by IDF, NCEP or ACE definition (tables 6-10 in
Additional files 3, 4, 5, 6, 7).
Discussion
Our data show distinct differences in the prevalence of
metabolic syndrome and the level of agreement between
the definitions that do not require the measurement of
insulin levels and the definitions that do require. The
novel aspect of our study is that the agreement among all
of these five published definitions has not been docu-
mented before and the analysis was conducted in a popu-
lation with a high prevalence of metabolic syndrome. The
variability in prevalence estimates reflects different cut-off
points and different combinations of criteria among vari-
ous definitions. The prevalence estimates of National
Cholesterol Education Program Adult Treatment Panel III,
American College of Endocrinology and International
Diabetes Federation definitions are close to each other.
ACE proposes to diagnose metabolic syndrome only in
individuals who are at increased risk of insulin resistance.
BMI over 25 kg/m2, sedentary lifestyle and a positive fam-
ily history of cardiovascular disease are among prerequi-
sites of ACE definition [11] and these are common
occurrences in the population. Ninety-seven percent of
our study population had one of the prerequisite condi-
tions of ACE definition. ACE and IDF definitions proved
to be almost identical in this study.
A health care provider has two alternative sets of meta-
bolic syndrome definitions whether he or she decides to
diagnose patients as having or not having the metabolic
syndrome: a definition that require an insulin assay and a
definition that do not require it. By restricting high risk
patients (the denominator) to individuals with high insu-
lin levels rather than the general population, WHO and
EGIR criteria identifies only insulin resistant individuals
Table 4: Anthropometric and biochemical data of subjects categorized as metabolic syndrome according to each studied definition.
WHO-MS EGIR-MS NCEP-MS ACE-MS IDF-MS
Age (years)* 47 ± 12 46 ± 12 48 ± 12 48 ± 12 48 ± 12
BMI (kg/m2) * 3 3  ±  53 3  ±  53 2  ±  43 1  ±  53 2  ±  5
SBP (mmHg)* 145 ± 22 144 ± 23 145 ± 24 143 ± 24 144 ± 25
DBP (mmHg)* 93 ± 12 92 ± 12 92 ± 12 91 ± 12 91 ± 12
Glucose (mmol/l)* 5.4 ± 0.6 5.3 ± 0.6 5.2 ± 0.6 5.1 ± 0.6 5.2 ± 0.6
Insulin (pmol/l)† 96.1 (81.6, 119.1) 96.1 (82.3, 118.6) 66.0 (47.4, 92.6) 63.9 (44.5, 90.4) 64.6 (45.9, 90.6)
HOMA-IR† 3.14 (2.64, 4.03) 3.12 (2.65, 4.03) 2.13 (1.48, 3.00) 2.00 (1.36, 2.89) 2.08 (1.44, 2.95)
Framingham risk 
score*
2.99 ± 4.64 2.79 ± 4.45 3.22 ± 4.81 3.08 ± 4.71 3.04 ± 4.67
Women:
Frequency‡ 18% 19% 43% 44% 48%
Waist (cm)* 102.8 ± 9.7 101.3 ± 10.1 99.6 ± 9.7 97.6 ± 10.9 98.2 ± 10.2
TC (mmol/l)* 4.99 ± 1.13 4.94 ± 1.13 4.95 ± 1.06 4.92 ± 1.10 4.91 ± 1.05
HDL-C (mmol/l)* 1.07 ± 0.26 1.06 ± 0.27 1.06 ± 0.23 1.05 ± 0.22 1.07 ± 0.23
LDL-C (mmol/l)* 3.06 ± 0.97 3.04 ± 0.96 3.09 ± 0.91 3.06 ± 0.95 3.05 ± 0.89
TG (mmol/l)† 1.72 (1.30, 2.34) 1.70 (1.26, 2.29) 1.59 (1.19, 2.13) 1.67 (1.21, 2.18) 1.57 (1.13, 2.07)
Men:
Frequency‡ 23% 25% 41% 48% 46%
Waist (cm)* 107.0 ± 8.3 106.9 ± 8.12 105.3 ± 8.5 102.9 ± 9.1 105.2 ± 7.1
TC (mmol/l)* 4.89 ± 0.91 4.85 ± 0.90 4.87 ± 0.84 4.78 ± 0.88 4.82 ± 0.90
HDL-C (mmol/l)* 0.92 ± 0.22 0.91 ± 0.22 0.89 ± 0.20 0.87 ± 0.19 0.91 ± 0.22
LDL-C (mmol/l)* 2.90 ± 0.81 2.88 ± 0.79 2.90 ± 0.74 2.83 ± 0.78 2.90 ± 0.80
TG (mmol/l)† 2.08 (1.52, 2.69) 2.05 (1.41, 2.62) 2.10 (1.69, 2.71) 2.03 (1.59, 2.68) 1.92 (1.42, 2.53)
Please see list of abbreviations used. *mean ± SD are given for normally distributed variables, †median (25th and 75th percentile values) are given for 
variables with a skewed distribution ‡the frequency of men or women with the metabolic syndrome according to each definition.BMC Public Health 2007, 7:353 http://www.biomedcentral.com/1471-2458/7/353
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with the metabolic syndrome and misses many individu-
als who are at increased risk of cardiovascular disease, but
without elevated insulin levels. We aimed to characterize
the subjects that are missed by the insulin measurement
requiring definitions. In our sample, there were more sub-
jects below the 75th percentile of the HOMA-IR or insulin
distribution, who had abdominal obesity, elevated blood
pressure, low HDL-C levels, elevated TC/HDL-C ratio or
elevated triglycerides. Metabolic syndrome components
of low HDL-C and high blood pressure are classical risk
factors for cardiovascular disease [1] and elevated triglyc-
eride levels are shown to be a predictor of cardiovascular
events in prospective studies in Turkey and elsewhere [31-
33]. Abdominal obesity and elevated waist circumference
has also been associated with increased CVD morbidity
[34,35]. In view of our data, we conclude that both WHO
and IDF definitions identify patients with insulin resist-
ance and increased cardiovascular risks factors, but IDF
definition identifies additional subjects, not identified by
WHO definition and these additional subjects are at
increased cardiovascular disease risk with lesser degree of
insulin resistance. When we replaced EGIR for WHO def-
inition and NCEP or ACE for IDF definition, we reached
to the same conclusion.
Relevant previous studies
San Antonio Heart Study, a prospective study with a
median follow-up period of 7.4 years showed that Fram-
ingham Risk Scoring System was better in predicting
future CVD events than the diagnosis of the metabolic
syndrome and NCEP, IDF and WHO definitions imparted
similar CVD and diabetes risks [5]. ACE and EGIR defini-
tions were not evaluated in the San Antonio Heart Study.
Hoorn Study, a prospective cohort study of diabetes and
diabetes complications in the Dutch population com-
pared NCEP, WHO, EGIR and ACE definitions with
respect to their association with 10-year risk of fatal and
nonfatal cardiovascular disease [4]. Hoorn Study Investi-
gators reported that NCEP definition was associated with
an approximately 2-fold risk of all end points in men and
of nonfatal CVD in women after adjustment for age. The
hazard ratios of the WHO, EGIR and ACE definitions for
all end points were slightly lower. In the Hoorn Study, the
kappa agreement between the definitions not requiring
insulin measurement (NCEP or ACE) and the definitions
requiring insulin measurement (WHO or EGIR) ranged
from 0.28 to 0.46 and was fair to moderate, a similar out-
come as our results. IDF definition was not evaluated by
the Hoorn Study, because it was not available at that time.
Table 5: Comparison among subjects free of metabolic syndrome, WHO-defined metabolic syndrome and surplus IDF-defined 
metabolic syndrome.
Parameter No-MS WHO-MS Surplus-MS (IDF) ANOVA p
Frequency (n) 50% (790) 20% (314) 30% (464)
Age (years) 42 ± 13 47 ± 12a 49 ± 13b <0.001
BMI (kg/m2) 27 ± 4 33 ± 5a 31 ± 4b,c <0.001
SBP (mmHg) 124 ± 19 145 ± 22a 142 ± 26b <0.001
DBP(mmHg) 80 ± 11 92 ± 12a 90 ± 12b,c <0.001
Glucose (mmol/l) 4.8 ± 0.4 5.4 ± 0.6a 5.0 ± 0.6b,c <0.001
Log insulin (pmol/l) 1.60 ± 0.22 2.01 ± 0.13a 1.69 ± 0.17b,c <0.001
Log HOMA-IR 0.07 ± 0.23 0.53 ± 0.14a 0.18 ± 0.18b,c <0.001
Framingham risk score 1.10 ± 1.87 2.99 ± 4.64a 2.93 ± 4.54b <0.001
Women:
Frequency (n) 51% (525) 18% (191) 31% (320)
Waist (cm) 86.0 ± 11.4 102.8 ± 9.7a 95.8 ± 9.5b,c <0.001
TC (mmol/l) 4.64 ± 1.06 4.99 ± 1.13a 4.86 ± 1.00b <0.001
HDL-C (mmol/l) 1.36 ± 0.31 1.07 ± 0.26a 1.09 ± 0.23b <0.001
LDL-C (mmol/l) 2.82 ± 0.92 3.06 ± 0.97a 3.04 ± 0.85b <0.001
Log TG (mmol/l) -0.02 ± 0.16 0.23 ± 0.19a 0.16 ± 0.19b,c <0.001
Men:
Frequency (n) 50% (265) 23% (123) 27% (144)
Waist (cm) 94.2 ± 9.8 107.0 ± 8.3a 103.1 ± 6.0b,c <0.001
TC (mmol/l) 4.57 ± 0.93 4.89 ± 0.91a 4.79 ± 0.94 0.004
HDL-C (mmol/l) 1.08 ± 0.24 0.92 ± 0.22a 0.92 ± 0.24b <0.001
LDL-C (mmol/l) 2.90 ± 0.82 2.90 ± 0.81 2.92 ± 0.84 0.957
Log TG (mmol/l) 0.07 ± 0.19 0.32 ± 0.23a 0.25 ± 0.22b,c <0.001
Please see list of abbreviations used. Data is presented as mean ± SD. No-MS: subjects free of metabolic syndrome (WHO and IDF negative), 
WHO-MS: metabolic syndrome by WHO definition, including subjects identified concordantly by IDF (WHO positive, IDF either positive or 
negative), surplus-MS: subjects identified additionally as metabolic syndrome by only IDF definition (WHO negative, IDF positive).
a: p < 0.05 No-MS vs. WHO-MS, estimated by post hoc Tukey's test
b: p < 0.05 No-MS vs. surplus-MS (IDF), estimated by post hoc Tukey's test
c: p < 0.05 WHO-MS vs. surplus-MS (IDF), estimated by post hoc Tukey's test.BMC Public Health 2007, 7:353 http://www.biomedcentral.com/1471-2458/7/353
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Guerrero-Romero and Rodriguez-Moran [22] found a
very good agreement (κ: 0.87) between NCEP and IDF
definitions and a moderate agreement (κ: 0.51) between
IDF and WHO definitions. They concluded that IDF defi-
nition has a low concordance with WHO definition and a
high concordance with NCEP definition and both NCEP
and IDF definitions identify similar proportions of sub-
jects with the metabolic syndrome. ACE and EGIR defini-
tions were not analyzed in that report [22]. In the Korean
Health and Examination Survey, the prevalence of the
metabolic syndrome was 18.8% by NCEP and 19.5% by
IDF definition. The agreement between NCEP and IDF
definitions was moderate (κ: 0.54) [19]. The difference in
the prevalence and agreement rates between the Korean
Health and Examination Survey and our results, may
probably be explained by the difference in the characteris-
tics of the study populations. Our data and the results of
other studies illustrate that the definitions with a similar
design have a very good agreement [5,16,19-22].
Limitations of the study
Our study is cross-sectional and compares CVD risk fac-
tors among metabolic syndrome definitions. There are
only few prospective studies with IDF criteria [5,16,18,36-
39], probably because it is a recently published definition.
More prospective studies comparing IDF definition with
others are needed. There have been no cross-sectional or
prospective studies comparing all of the five published
definitions of the metabolic syndrome, although there are
some studies involving two to four of the definitions [4-
7,14,16-24,36-39]. Another limitation of our study is that
the insulin sensitivity is determined by HOMA-IR, a for-
mula not perfectly correlated with the gold standard
method, insulin sensitivity index derived from hyperin-
sulinemic euglycemic clamp. Studies show that the corre-
lation between HOMA-IR value and the insulin sensitivity
index range from 0.69 to 0.79 [40,41]. However, HOMA-
IR calculation is more feasible for epidemiologic studies
involving large number of participants. Microalbuminu-
ria was not determined and not counted as a component
in WHO definition in our study. Microalbuminuria is a
predictor of future cardiovascular events [9,42]. In Insulin
Resistance Atherosclerosis Study, only 6% of participants
without diabetes had evidence of microalbuminuria [14].
Therefore, the effect of inclusion or exclusion of micro-
albuminuria in defining metabolic syndrome in subjects
with normoglycemia appears minimal. The prevalence of
impaired glucose tolerance was reported as 6.7% in the
Turkish Diabetes Epidemiology Study (TURDEP), a
nationwide population based cross-sectional study [43].
As we did not perform oral glucose tolerance testing, we
may have underestimated the prevalence of metabolic
syndrome, up to 6.7% for ACE, EGIR or WHO definitions.
Some of the subjects with impaired glucose tolerance or
microalbuminuria may nevertheless have been catego-
rized as metabolic syndrome cases in our analyses,
because they may have met other components of ACE,
EGIR or WHO definitions.
Previous studies have shown widely varying estimates of
the prevalence of metabolic syndrome, because of dissim-
ilar definitions and populations: from 5% in Chinese men
to 39% in Western populations [17,23]. Although our aim
was not to document the prevalence of metabolic syn-
drome and our sample was not nationally representative,
our results are in line with previous population based epi-
demiologic studies from Turkey, reporting a prevalence
rate between 33 to 39% [44-46]. The prevalence of meta-
bolic syndrome was reported as 37% in Greece [47], a
neighbor country of Turkey. Although Turkey is a devel-
oping country, the age standardized cardiovascular death
rate is estimated to rank among the highest in Europe
[48]. The Turkish population has a cardiovascular disease
risk factor profile that distinctly differs from that of West-
ern populations, as the relative role of the metabolic syn-
drome and atherogenic dyslipidemia is more pronounced
[48]. The leading independent predictors of CVD morbid-
ity and mortality are related to the metabolic syndrome
[45].
Conclusion
National Cholesterol Education Program Adult Treatment
Panel III, International Diabetes Federation and American
College of Endocrinology definitions of the metabolic
syndrome, the definitions that do not require the meas-
urement of insulin levels have substantial to very good
agreement and capture more individuals at increased car-
diometabolic risk than the definitions that require insulin
measurement. The agreement between World Health
Organization and European Group for Study of Insulin
Resistance definitions, the definitions that require the
measurement of insulin sensitivity and fasting insulin lev-
els is very good. In view of our data, we agree with NCEP,
ACE and IDF and recommend the clinical use of defini-
tions that do not require the measurement of insulin lev-
els.
List of abbreviations used
ACE: American College of Endocrinology, BMI: body
mass index, BP: blood pressure, CVD: cardiovascular dis-
ease, DBP: diastolic blood pressure, DM: diabetes melli-
tus, EGIR: European Group for the Study of Insulin
Resistance, HDL-C: high density lipoprotein cholesterol,
HOMA-IR: homeostasis model assessment of insulin
resistance, IDF: International Diabetes Federation, IFG:
impaired fasting glucose, IGT: impaired glucose tolerance,
IR: insulin resistance, LDL-C: low density lipoprotein cho-
lesterol, MS: metabolic syndrome, NCEP: National Cho-
lesterol Education Program, SBP: systolic blood pressure,
SD: standard deviation, TC: total cholesterol, TG: triglyc-BMC Public Health 2007, 7:353 http://www.biomedcentral.com/1471-2458/7/353
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eride, WC: waist circumference, WHO: World Health
Organization, WHR: waist to hip ratio.
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